Key points are not available for this paper at this time.
Dolutegravir plus abacavir-lamivudine had a better safety profile and was more effective through 48 weeks than the regimen with efavirenz-tenofovir DF-emtricitabine. (Funded by ViiV Healthcare; SINGLE ClinicalTrials.gov number, NCT01263015 .).
Building similarity graph...
Analyzing shared references across papers
Loading...
Sharon Walmsley
University Health Network
Antonio Antela
Universidade de Santiago de Compostela
Nathan Clumeck
University of North Carolina at Chapel Hill
New England Journal of Medicine
University Health Network
Research Triangle Park Foundation
University of Nebraska Medical Center
Building similarity graph...
Analyzing shared references across papers
Loading...
Walmsley et al. (Wed,) studied this question.
synapsesocial.com/papers/69d91df1da3af5b1d0835aa0 — DOI: https://doi.org/10.1056/nejmoa1215541
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: